Cargando…

Tafamidis delays neurological progression comparably across Val30Met and non‐Val30Met genotypes in transthyretin familial amyloid polyneuropathy

BACKGROUND AND PURPOSE: To better characterize the effects of tafamidis in non‐Val30Met patients with transthyretin familial amyloid polyneuropathy, this post hoc analysis compared the neurological results from a 12‐month, open‐label study of non‐Val30Met versus Val30Met patients at month 12 from th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gundapaneni, B. K., Sultan, M. B., Keohane, D. J., Schwartz, J. H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5838526/ https://www.ncbi.nlm.nih.gov/pubmed/29115008 http://dx.doi.org/10.1111/ene.13510

Ejemplares similares

Vasculopathy in transthyretin Val30Met familial amyloid polyneuropathy
por: Koike, Haruki, et al.
Publicado: (2015)

Effects of Tafamidis on Transthyretin Stabilization and Clinical Outcomes in Patients with Non-Val30Met Transthyretin Amyloidosis
por: Merlini, Giampaolo, et al.
Publicado: (2013)

Amyloid fibril composition within hereditary Val30Met (p. Val50Met) transthyretin amyloidosis families
por: Suhr, Ole Bernt, et al.
Publicado: (2019)

Amyloid fibril composition type is consistent over time in patients with Val30Met (p.Val50Met) transthyretin amyloidosis
por: Anan, Intissar, et al.
Publicado: (2022)

Early intervention with tafamidis provides long-term benefit in delaying neurological progression in patients with transthyretin familial amyloid polyneuropathy
por: Waddington-Cruz, Marcia, et al.
Publicado: (2015)

Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy
por: Waddington Cruz, Márcia, et al.
Publicado: (2016)

Influence of baseline neurologic severity on disease progression and the associated disease-modifying effects of tafamidis in patients with transthyretin amyloid polyneuropathy
por: Amass, Leslie, et al.
Publicado: (2018)

Cardiac Findings and Events Observed in an Open-Label Clinical Trial of Tafamidis in Patients with non-Val30Met and non-Val122Ile Hereditary Transthyretin Amyloidosis
por: Damy, Thibaud, et al.
Publicado: (2015)

Clinicopathological correlations of sural nerve biopsies in TTR Val30Met familial amyloid polyneuropathy
por: Fernandes, Armindo, et al.
Publicado: (2019)

Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: supportive post-hoc analyses of a pivotal trial
por: Keohane, Denis, et al.
Publicado: (2015)

Vitreous Amyloidosis as the Presenting Symptom of Familial Amyloid Polyneuropathy TTR Val30Met in a Portuguese Patient
por: Seca, Mariana, et al.
Publicado: (2014)

Macular and optic disc edema and retinal vascular leakage in familial amyloid polyneuropathy with a transthyretin Val30Met mutation: a case report
por: Dias-Santos, Arnaldo, et al.
Publicado: (2014)

Widespread Cardiac and Vasomotor Autonomic Dysfunction in Non-Val30Met Hereditary Transthyretin Amyloidosis
por: Koike, Haruki, et al.
Publicado: (2018)

Neurophysiological pitfalls in TTR-FAP Val30Met
por: Conceição, Isabel, et al.
Publicado: (2015)

Neurophysiological pitfalls in TTR-FAP Val30Met
por: Conceição, Isabel, et al.
Publicado: (2015)

Positive real-world effectiveness of tafamidis for delaying disease progression in transthyretin familial amyloid polyneuropathy
por: Stewart, Michelle, et al.
Publicado: (2015)

Non‐Val30Met mutation, septal hypertrophy, and cardiac denervation in patients with mutant transthyretin amyloidosis
por: Hirakawa, Kyoko, et al.
Publicado: (2018)

Long-term surgical results of trabeculectomy for secondary glaucoma in Val30Met hereditary transthyretin amyloidosis
por: Kitahara, Junya, et al.
Publicado: (2023)

Phenotypes Associated With the Val122Ile, Leu58His, and Late-Onset Val30Met Variants in Patients With Hereditary Transthyretin Amyloidosis
por: Zampino, Serena, et al.
Publicado: (2023)

Late-Onset Hereditary Transthyretin Amyloidosis Val30Met in an Elderly Person in a Non-Endemic Area
por: Wang, Shun, et al.
Publicado: (2022)

Suture trabeculotomy ab interno for secondary glaucoma in Japanese patients with Val30Met hereditary transthyretin amyloidosis
por: Kawaji, Takahiro, et al.
Publicado: (2022)

Positive Effectiveness of Tafamidis in Delaying Disease Progression in Transthyretin Familial Amyloid Polyneuropathy up to 2 Years: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
por: Mundayat, Rajiv, et al.
Publicado: (2018)

Characteristics of Patients with Late- vs. Early-Onset Val30Met Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
por: Waddington-Cruz, Márcia, et al.
Publicado: (2021)

Tafamidis for a Transplant Patient with Transthyretin Amyloid Polyneuropathy
por: Romero-Imbroda, Jesús, et al.
Publicado: (2017)

Urinary Transthyretin as a Biomarker in ATTRv Val50Met Amyloidosis
por: Matsushita, Hiroaki, et al.
Publicado: (2022)

Treatment With Tafamidis Slows Disease Progression in Early-Stage Transthyretin Cardiomyopathy
por: Sultan, Marla B, et al.
Publicado: (2017)

Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy
por: Coelho, Teresa, et al.
Publicado: (2013)

Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy
por: Elliott, Perry, et al.
Publicado: (2021)

Tafamidis, a Noninvasive Therapy for Delaying Transthyretin Familial Amyloid Polyneuropathy: Systematic Review and Meta-Analysis
por: Zhao, Yinan, et al.
Publicado: (2019)

Molecular dynamics simulation study of AG10 and tafamidis binding to the Val122Ile transthyretin variant
por: Morris, Kevin F., et al.
Publicado: (2020)

Val50Met hereditary transthyretin amyloidosis: not just a medical problem, but a psychosocial burden
por: González-Moreno, Juan, et al.
Publicado: (2021)

Updated Evaluation of the Safety, Efficacy and Tolerability of Tafamidis in the Treatment of Hereditary Transthyretin Amyloid Polyneuropathy
por: Falcão de Campos, Catarina, et al.
Publicado: (2023)

Post Hoc Analysis of Nutritional Status in Patients with Transthyretin Familial Amyloid Polyneuropathy: Impact of Tafamidis
por: Suhr, Ole B., et al.
Publicado: (2014)

Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) and long‐term extension study
por: Damy, Thibaud, et al.
Publicado: (2020)

Catechol-O-Methyltransferase Val158Met and brain-derived neurotrophic factor Val66Met gene polymorphisms in paraphilic sexual offenders
por: Cengiz, Mujgan, et al.
Publicado: (2019)

Survival After Transplantation in Patients With Mutations Other Than Val30Met: Extracts From the FAP World Transplant Registry
por: Suhr, Ole B., et al.
Publicado: (2016)

Relationship between the COMT-Val158Met and BDNF-Val66Met Polymorphisms, Childhood Trauma and Psychotic Experiences in an Adolescent General Population Sample
por: Ramsay, Hugh, et al.
Publicado: (2013)

Association of COMT Val(108/158)Met Genotype and Cigarette Smoking in Pregnant Women
por: Munafò, Marcus R., et al.
Publicado: (2011)

The influence of COMT Val(158)Met genotype on the character dimension cooperativeness in healthy females
por: Baeken, Chris, et al.
Publicado: (2014)

Effect of the COMT Val158Met genotype on lateral prefrontal activations in young children
por: Moriguchi, Yusuke, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_scmbs8a9ufp78rc67ias0sagnq